Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
D.A.S.T. BIOTECH PHARM
Suzhou, China
- Ownership
- Private
- Development stage
- Other
01
Overview
DAST Biotech is an early-stage biotechnology company focused on the development of innovative therapies for metabolic diseases, including type 2 diabetes and obesity. The company specializes in the design of multi-agonist peptides and small molecules targeting key metabolic receptors such as GLP-1, GIP, and Glucagon. DAST Biotech aims to leverage its expertise in peptide engineering to create next-generation treatments with improved efficacy and safety profiles. The company's research and development efforts are primarily centered on addressing the growing global burden of metabolic and endocrine disorders.
- Therapeutic areas
- EndocrinologyGastroenterologyMetabolic Disorders
- Modalities
- Small moleculePeptidesBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on D.A.S.T. BIOTECH PHARM.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on D.A.S.T. BIOTECH PHARM.